

BrainChip – Director Share Donation

Sydney, Australia– June 09, 2022 – ASX: BRN, OTCQX: BRCHF, ADR: BCHPY

BrainChip Holdings Ltd, the world's first commercial producer of ultra-low power neuromorphic AI IP, today announced that BrainChip founder and Chief Technology Officer Peter van der Made has made a personal donation of 3,500,000 BrainChip Ordinary Shares to the Lions Alzheimer's Foundation in Australia.

Mr van der Made said, "This donation is intended to provide funding for the continued research of Dr Ralph Martins and his team at the Lions Alzheimer's Foundation in Perth. Alzheimer's Disease is an insidious affliction that robs patients of their memories and their quality of life. My father had Alzheimer's Disease and his suffering impacted me and my family profoundly. I've dedicated my professional life to the study of the human brain, so this donation is my way of contributing to the ongoing research to find a cure for this terrible disease."

The share donation was approved by the BrainChip board, and the shares were transferred through Share Gift Australia, where they have been sold on market in five tranches of 700,000 shares per tranche, over a five (5) day period between 03 June 2022 and 08 June 2022.

Based on the share price at the time of the sale, the sales have raised approximately \$3.6 million dollars for the Lions Alzheimer's Foundation. Mr van der Made is personally paying all taxes associated with the donation of shares to the Lions Alzheimers Foundation.

Dr Ralph Martins said, "I am deeply grateful to Peter for making this generous donation to the Lions Alzheimer's Foundation to support and advance our research programs for the early Diagnosis, Prevention and Treatment of Alzheimer's disease. In my 38 year career working on Alzheimer's disease research this is the single largest donation second only to Malcolm McCusker and his family who funded the establishment of my research team over several years. We are on the cusp of major breakthroughs for Alzheimer's and Dementia and this wonderful gift from Peter will hopefully lead to other generous donors coming forward to enable us to develop a blood test for the early detection of Alzheimer's and implement effective prevention programs for the wider community."

This announcement is authorised for release by the BRN Board of Directors.

About BrainChip Holdings Ltd (ASX:BRN)

BrainChip is a global technology company that is producing a groundbreaking neuromorphic processor that brings artificial intelligence to the edge in a way that is beyond the capabilities of other products. The chip is high performance, small, ultra-low power and enables a wide array of edge capabilities that include on-chip training, learning and inference. The event-based neural network processor is inspired by the spiking nature of the human brain and is implemented in an industry standard digital process. By mimicking brain processing BrainChip has pioneered a processing architecture, called Akida™, which is both scalable and flexible to address the requirements in edge devices. At the edge, sensor inputs are analyzed at the point of acquisition rather than through transmission via the cloud to a data center. Akida is designed to provide a complete ultra-low power and fast AI Edge Network for vision, audio, olfactory and smart transducer applications. The reduction in system latency provides faster response and a more power efficient system that can reduce the large carbon footprint of data centers.

Additional information is available at:

<https://www.brainchipinc.com>

Investor Relations Contact: IR@brainchip.com

Follow BrainChip on Twitter: https://www.twitter.com/BrainChip_inc

Follow BrainChip on LinkedIn: <https://www.linkedin.com/company/7792006>

Company contact:

Tony Dawe

IR@brainchip.com

+61 405 989 743

-